BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 19.07.2013

Narcolepsy Public Meeting on Patient-Focused Drug Development

The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for narcolepsy. Patient-Focused Drug Development is part of FDA's performance commitments in the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patients' perspectives on the impact of narcolepsy on daily life as well as the available therapies for narcolepsy.

Source: Federal Register — Food and Drug AdministrationOpen original release →